IP Library Granted Patent US 11,304,910
Granted Patent B2
US 11,304,910 · App. 15/781,708 · Granted Apr 19, 2022

Soft gelatin capsules with pH-independent release

Inventors: Simone Carucci (Lugano, CH); Maurizio Marchiorri (Lugano, CH); Marco Pontiggia (Lugano, CH); Tiziano Fossati (Lugano, CH)
Assignee: Altergon S.A.
A61K9/4825A61K9/4866A61K31/198A61K45/06A61K47/02A61K47/10A61K47/26A61K47/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,304,910
App. No.
15/781,708
Granted
Apr 19, 2022
Kind
B2
Abstract

Disclosed are soft gelatin capsules comprising a gelatin shell, a plasticiser, water, and optionally a calcium salt and a filling containing a dispersed or solubilised medicament comprising gelatin with gelling power, hydrolysed gelatin, glycerol, water, pectin and gellan gum. The formulations according to the invention allow gradual release of the active ingredient, regardless of pH.

Claims (12)

1. A soft gelatin capsule, wherein the capsule comprises

a shell containing gelatin, a plasticizer, water and a calcium salt and

a filling,

wherein the filling contains a medicament dispersed or solubilised in a hydrophilic filling comprising from 1 to 5% of gelatin having a Bloom value ranging from 60 to 150 in percentages, said gelatin having gelling power, from 10 to 30% of hydrolyzed gelatin, from 10 to 30% of 85% glycerol, from 20 to 60% water, from 10 to 30% of pectin, up to 5% of gellan gum and from 0.1 to 10% of alcohol, the percentages being expressed by weight, on the total filling weight, wherein said soft gelatin capsule allows, in vitro, releasing of said medicament in a sustained pH-independent manner, said releasing beginning at the release time of said medicament and continuing for up to 360 minutes.

2. A capsule according to claim 1 wherein the medicament can be dispersed or solubilised by means of ethanol or other hydrophilic or lipophilic solvents, and/or complexed with cyclodextrin.

3. A capsule according to claim 1 wherein the shell contains calcium chloride.

4. A capsule according to claim 1 , wherein the medicament is selected from non-steroidal anti-inflammatory drugs, thyroid hormones, statins, bronchodilators, antihistamines, steroids, narcotic analgesics, antibacterials/antivirals, vitamins, oils of various kinds, glycosaminoglycans, antimycotics, proton pump inhibitors, fertility hormones, corticosteroids, erectile dysfunction medicaments, and anticoagulants.

5. A capsule according to claim 1 wherein the she contains from 20 to 45% of gelatin having a Bloom value ranging from 110 to 300, plasticizer from 15 to 30%, water from 30 to 40% and a calcium salt, the percentages being on the total shell weight.

6. A capsule according to claim 5 wherein the calcium salt is calcium chloride.

7. A capsule according to claim 6 wherein calcium chloride is present in percentages by weight ranging from 0.5 to 5% on the total shell weight.

8. A capsule according to claim 1 , wherein the plasticizer is selected from anhydrous glycerol, sorbitol, sorbitol/sorbitan mixtures, 1,2 propylene glycol, macrogol 200-600 and mixtures thereof.

9. A capsule according to claim 8 wherein the plasticizer is anhydrous glycerol.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2025
From: ALTERGON SA
To: IBSA INSTITUT BIOCHIMIQUE SA
Reel/Frame 071736/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2018
From: CARUCCI, SIMONE; MARCHIORRI, MAURIZIO; PONTIGGIA, MARCO; FOSSATI, TIZIANO
To: ALTERGON S.A.
Reel/Frame 045995/0239 →
Priority Claims (1)
IT 102015000081410 · Dec 9, 2015 · national
Continuity (1)
Related Publication 20180353432A1 · Dec 13, 2018